Association of plasma F2-isoprostanes and isofurans concentrations with erythropoiesis-stimulating agent resistance in maintenance hemodialysis patients

Table 5 Association of quartiles of baseline markers of inflammation with baseline ESA resistance index (ERI) in maintenance hemodialysis patients

	Concentration	Model 1^a			Model 2^b			Model 3^c
	Concentration	β	95 % CI	P-value^d	β	95 % CI	P-value^d	β	95 % CI	P-value^d
hsCRP (mg/l)	<19.8	Reference	-	-	Reference	-	-	Reference	-	-
	19.8–<45.7	3.32	−1.44, 8.08	0.17	2.92	−2.42, 8.25	0.28	3.49	−1.98, 8.95	0.21
	45.7–<101	3.34	−1.59, 8.27	0.18	4.98	−1.27, 11.24	0.12	4.93	−1.32, 11.2	0.12
	≥101	8.45	1.63, 15.3	0.02	7.84	−0.38, 16.1	0.06	7.40	−0.04, 14.8	0.05
IL-6 (pg/ml)	<8.3	Reference	-	-	Reference	-	-	Reference	-	-
	8.3–<13.1	2.20	−2.38, 6.78	0.34	2.49	−2.81, 7.80	0.35	3.78	−2.02, 9.57	0.19
	13.1–<20.9	5.17	0.70, 9.64	0.02	2.59	−3.42, 8.59	0.39	2.36	−3.44, 8.16	0.42
	≥20.9	9.15	2.78, 15.5	0.005	8.00	0.52, 15.5	0.04	7.82	0.86, 14.8	0.03

ERI defined as the weekly weight-adjusted ESA dose (units/kg/week) divided by the baseline hemoglobin level (g/dl)
ESA erythropoeisis stimulating agent, hsCRP high-sensitivity C-reactive protein, IL-6 Interleukin-6
^a Unadjusted
^b Adjusted for age, sex, race, body mass index, etiology of end stage renal disease, diabetes status, transferrin saturation (serum iron/total iron binding capacity), Kt/V, and serum parathyroid hormone
^c Adjusted for Model 2 covariates plus isofurans
^d P-values obtained from comparing regression coefficients to coefficient for lowest quartile of each inflammatory marker

ISSN: 1471-2369